A randomized, multicenter, open-label cross-over study to evaluate participant and healthcare professional reported preference for subcutaneous atezolizumab compared with intravenous atezolizumab formulation in participants with non-small cell lung cancer (NSCLC).

Condition: Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Genetech_Roche

Phase:

A randomized, multicenter, open-label cross-over study to evaluate participant and healthcare professional reported preference for subcutaneous atezolizumab compared with intravenous atezolizumab formulation in participants with non-small cell lung cancer (NSCLC).